Patient enrolment
panretinal, allergy, peripheral retinal ischemia, opacity, cataract, CMT, epiretinal, loss of vision
DISEASES, DIABETES MELLITUS, OPACITY, ALLERGY, CATARACT, EAR, MACULAR OEDEMA, EYE, LOSS OF VISION
This study was conducted in accordance with the Declaration of Helsinki and was approved by the Human Research Ethics Committees of Sydney Local Area Health Service, the University of Sydney and the Royal Victorian Eye and Ear Hospital (RVEEH) in Melbourne (Protocol number X14-0157). An independent safety monitoring committee reviewed safety data. Patients were recruited from the Sydney Eye Hospital and the RVEEH clinics from 2016 to 2018. All patients had a diagnosis of diabetes mellitus, were older than 18 years and completed written informed consent. Inclusion criteria included: Eyes with CMT > 300 microns on ocular coherence tomography (OCT), BCVA of 35–79 LogMAR letters and peripheral retinal ischemia affecting an area greater than 10-disc diameters on wide-field fundus fluorescein angiogram (FFA). Exclusion criteria included loss of vision due or macular oedema due to other causes, vitreomacular traction or significant epiretinal membrane. Study eye exclusion criteria included: treatment within 6-months with intravitreal triamcinolone or 3-months with anti-VEGF, cataract surgery within 3 months, previous panretinal photocoagulation (PRP) laser or vitrectomy, or media opacity that precluded adequate macular photography. Other exclusion criteria of the patient included pregnancy, unwillingness to use adequate contraception, allergy to fluorescein or aflibercept or intercurrent severe medical diseases.